Stockscreener 앱 받기
160.29
1.98%
3.3968
전일 마감가:
$156.89
열려 있는:
$159.12
하루 거래량:
1.37M
Relative Volume:
0.49
시가총액:
$248.56B
수익:
$60.48B
순이익/손실:
$10.40B
주가수익비율:
48.14
EPS:
3.3297
순현금흐름:
$8.05B
1주 성능:
+0.79%
1개월 성능:
-5.27%
6개월 성능:
-23.32%
1년 성능:
+102.22%
1일 변동 폭
$158.98
$160.41
1주일 범위
$154.53
$160.39
52주 변동 폭
$72.89
$212.71
아스트라제네카 ADR Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
160.27 | 242.64B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,218.28 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
270.95 | 627.42B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
258.08 | 440.83B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
135.15 | 335.14B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.91 | 286.78B | 54.66B | 13.58B | 16.05B | 7.0171 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 개시 | Citigroup | Buy |
| 2025-10-27 | 재개 | Jefferies | Buy |
| 2025-10-16 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
AstraZeneca maintains Citi 'buy' rating despite mixed pipeline updates - Proactive financial news
AstraZeneca stock edges higher as Q2 2026 growth and EPS gains offset lung cancer trial setback - AD HOC NEWS
Why Is AstraZeneca (LSE:AZN) Anchoring London's Healthcare Trade Today? - Kalkine Media
AstraZeneca’s win in lung cancer; Sandoz inks a China deal - Yahoo Finance
Did AstraZeneca's (LSE:AZN) Lung Cancer Data Just Reset The Blue-Chip Mood Today? - Kalkine Media
AstraZeneca stock rises on lung cancer trial news - AD HOC NEWS
Can AstraZeneca (LSE:AZN) And GSK (LSE:GSK) Turn Regulatory Review Into Durable Progress? - Kalkine Media
Can Shell (LSE:SHEL) And AstraZeneca (LSE:AZN) Turn Capital Allocation Into Durable Progress? - Kalkine Media
Health Care Down on Growth DoubtsHealth Care Roundup - marketscreener.com
AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth - Morningstar
AstraZeneca Halts Key Lung-Cancer Trial--But Shares Barely Flinch - GuruFocus
AstraZeneca Halts Phase III Lung Cancer Trial as Drug Falls Short Against Keytruda - finance.biggo.com
AstraZeneca abandons lung cancer treatment trial in fresh setback for drugs giant - Yahoo Finance UK
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer - BioPharma Dive
UK Shares Start Week Downbeat; AstraZeneca Shares Data from Lung Cancer Trials - marketscreener.com
AstraZeneca stock gains on lung cancer trial news - ad-hoc-news.de
AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies - Benzinga
Market Wrap: EU chip stocks surge on Anthropic's earnings! AstraZeneca halts trials for lung cancer therapy (17.08.2026) - XTB.com
AstraZeneca (AZN) drug delays progression in first-line HER2 lung cancer - Stock Titan
AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda - Clinical Trials Arena
AstraZeneca (NYSE: AZN) halts lung trial after survival goals seen unlikely - Stock Titan
Lung cancer trial success puts AstraZeneca (AZN) drug duo in play - Stock Titan
Plato Investment Management Ltd Takes $5.90 Million Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca halts lung cancer trial in fresh pipeline setback - Proactive financial news
AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review -- Update - marketscreener.com
FTSE 100 Gains Support From Miners, AstraZeneca And Rolls-Royce - DirectorsTalk Interviews
AstraZeneca PLC (AZN) Stock Analysis: Exploring a 36.59% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
AstraZeneca Stops Cancer Drug Trial as Success Seen Unlikely - Bloomberg.com
AstraZeneca Halts Lung Cancer Trial for Volrustomig; Reports Positive Data for Tagrisso Combo, Enhertu - Yahoo Finance UK
AstraZeneca halts lung trial as two cancer drugs show positive results - marketscreener.com
AstraZeneca (LSE:AZN) Puts Blue-Chip Stocks Under An Earnings-Quality Spotlight - Kalkine Media
AstraZeneca Reports Positive Results with Lung Cancer Drugs - marketscreener.com
AstraZeneca scraps late-stage lung cancer trial after data setback - Investing.com Nigeria
Why is AstraZeneca stock up today? By Investing.com - Investing.com UK
Triple news for AstraZeneca - marketscreener.com
AstraZeneca reports Phase III survival benefit for Tagrisso–Orpathys lung cancer combination - Yahoo Finance UK
AstraZeneca, Daiichi Sankyo's Enhertu Improves Progression-free Survival in Late-stage Lung Cancer Trial - marketscreener.com
AstraZeneca discontinues lung cancer trial of volrustomig - Investing.com Nigeria
AstraZeneca ends one trial; Telecom Plus backs view - marketscreener.com
AstraZeneca lung cancer drug combination extends survival in trial - Proactive financial news
AstraZeneca discontinues lung cancer trial of volrustomig By Investing.com - Investing.com UK
AstraZeneca’s Tagrisso plus Orpathys extends survival in lung cancer - Investing.com Nigeria
AstraZeneca reports positive Phase III results for Tagrisso-Orpathys lung cancer combination - DirectorsTalk Interviews
AstraZeneca Ends Late-stage Metastatic Non-small Cell Lung Cancer Trial - marketscreener.com
REGAstraZeneca PLCUpdate on eVOLVE-Lung02 Phase III trial - TradingView
Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial - AstraZeneca
Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer - AstraZeneca
S&CO Inc. Takes Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca up significantly this week: Key Trends Investors Should Watch - Kalkine Media
AstraZeneca Joins States Aiming To Block Ill. 340B Drug Law - Law360
AstraZeneca slips Friday, underperforms market - MarketWatch
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.26%
0.48%
자본화:
|
볼륨(24시간):